Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results.
van der Laan A, Hirsch A, Nijveldt R, van der Vleuten PA, van der Giessen WJ, Doevendans PA, Waltenberger J, Ten Berg JM, Aengevaeren WR, Zwaginga JJ, Biemond BJ, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ. van der Laan A, et al. Among authors: doevendans pa. Neth Heart J. 2008 Dec;16(12):436-9. doi: 10.1007/BF03086194. Neth Heart J. 2008. PMID: 19127324 Free PMC article.
Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial--a prospective, multicenter, randomized trial.
Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC, Tijssen JG, Zijlstra F, Piek JJ; HEBE investigators. Hirsch A, et al. Among authors: doevendans pa. Am Heart J. 2006 Sep;152(3):434-41. doi: 10.1016/j.ahj.2006.02.007. Am Heart J. 2006. PMID: 16923409
Inflammation and apoptosis genes and the risk of restenosis after percutaneous coronary intervention.
Monraats PS, de Vries F, de Jong LW, Pons D, Sewgobind VD, Zwinderman AH, de Maat MP, 't Hart LM, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Frants RR, van der Laarse A, van der Wall EE, Wouter Jukema J. Monraats PS, et al. Among authors: doevendans pa. Pharmacogenet Genomics. 2006 Oct;16(10):747-54. doi: 10.1097/01.fpc.0000220572.28585.5e. Pharmacogenet Genomics. 2006. PMID: 17001294
Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention.
Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, Huizinga TW, Eefting D, Quax PH, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. Monraats PS, et al. Among authors: doevendans pa. Genes Immun. 2007 Jan;8(1):44-50. doi: 10.1038/sj.gene.6364343. Epub 2006 Nov 23. Genes Immun. 2007. PMID: 17122782
Does folate therapy reduce the risk of coronary restenosis?
van Hattum ES, Doevendans PA, Moll FL. van Hattum ES, et al. Among authors: doevendans pa. Neth Heart J. 2007 Jan;15(1):12-5. doi: 10.1007/BF03086052. Neth Heart J. 2007. PMID: 17612702 Free PMC article.
Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction.
Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP. Timmers L, et al. Among authors: doevendans pa. Circ Res. 2008 Feb 1;102(2):257-64. doi: 10.1161/CIRCRESAHA.107.158220. Epub 2007 Nov 15. Circ Res. 2008. PMID: 18007026
846 results